MaxCyte Inc
MXCT1.630USD
+0.130+8.67%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
173.83MMarket Cap
LossP/E TTM
More Details of MaxCyte Inc Company
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
MaxCyte Inc Info
Ticker SymbolMXCT
Company nameMaxCyte Inc
IPO dateMar 29, 2016
CEOMasoud (Maher)
Number of employees114
Security typeOrdinary Share
Fiscal year-endMar 29
Address9713 Key West Avenue,
CityROCKVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20850
Phone13015175556
Websitehttps://www.maxcyte.com/
Ticker SymbolMXCT
IPO dateMar 29, 2016
CEOMasoud (Maher)
Company Executives of MaxCyte Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+33.52%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+53.13%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
--
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
39.89K
+86.70%
Ms. Cynthia L. Collins
Ms. Cynthia L. Collins
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Patrick J. Balthrop
Mr. Patrick J. Balthrop
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+33.52%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+53.13%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
By BusinessUSD
Name
Revenue
Proportion
Product sales
5.27M
61.94%
Licenses
2.93M
34.42%
other
310.00K
3.64%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product sales
5.27M
61.94%
Licenses
2.93M
34.42%
other
310.00K
3.64%
Shareholding Stats
Updated: Mon, Dec 1
Updated: Mon, Dec 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cadian Capital Management LP
7.71%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.24%
River Global Investors LLP
5.15%
Other
66.67%
Shareholders
Shareholders
Proportion
Cadian Capital Management LP
7.71%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.24%
River Global Investors LLP
5.15%
Other
66.67%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
24.33%
Investment Advisor
22.61%
Hedge Fund
17.87%
Research Firm
4.86%
Private Equity
4.73%
Individual Investor
1.74%
Venture Capital
0.36%
Bank and Trust
0.19%
Pension Fund
0.15%
Other
23.16%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
287
82.96M
77.85%
-17.02M
2025Q2
296
78.80M
73.92%
-18.62M
2025Q1
308
82.56M
77.59%
-14.89M
2024Q4
308
80.42M
75.91%
-14.30M
2024Q3
300
80.65M
76.72%
-18.62M
2024Q2
297
80.25M
76.66%
-17.97M
2024Q1
302
79.09M
75.86%
-22.52M
2023Q4
303
79.97M
77.01%
-14.24M
2023Q3
292
77.05M
74.47%
-17.27M
2023Q2
284
79.82M
77.43%
-11.81M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cadian Capital Management LP
8.91M
8.36%
-1.11M
-11.10%
Jun 30, 2025
Mirabella Financial Services LLP
6.60M
6.19%
+2.90M
+78.38%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.21M
7.7%
+793.69K
+10.70%
Jun 30, 2025
The Vanguard Group, Inc.
5.60M
5.25%
+36.02K
+0.65%
Jun 30, 2025
River Global Investors LLP
3.25M
3.05%
+1.19M
+57.73%
Dec 31, 2024
Vitruvian Partners LLP
5.04M
4.73%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
4.23M
3.97%
+795.36K
+23.12%
Jun 30, 2025
Mudita Advisors LLP
3.37M
3.16%
+42.25K
+1.27%
Jun 30, 2025
AXA Investment Managers UK Ltd.
2.20M
2.07%
+1.22M
+123.16%
Jun 30, 2025
AXA Investment Managers Paris
2.20M
2.07%
--
--
Jul 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.6%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.6%
iShares Micro-Cap ETF
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
Avantis US Small Cap Equity ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of MaxCyte Inc?
The top five shareholders of MaxCyte Inc are:
Cadian Capital Management LP holds 8.91M shares, accounting for 8.36% of the total shares.
Mirabella Financial Services LLP holds 6.60M shares, accounting for 6.19% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.21M shares, accounting for 7.70% of the total shares.
The Vanguard Group, Inc. holds 5.60M shares, accounting for 5.25% of the total shares.
River Global Investors LLP holds 3.25M shares, accounting for 3.05% of the total shares.
Cadian Capital Management LP holds 8.91M shares, accounting for 8.36% of the total shares.
Mirabella Financial Services LLP holds 6.60M shares, accounting for 6.19% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.21M shares, accounting for 7.70% of the total shares.
The Vanguard Group, Inc. holds 5.60M shares, accounting for 5.25% of the total shares.
River Global Investors LLP holds 3.25M shares, accounting for 3.05% of the total shares.
What are the top three shareholder types of MaxCyte Inc?
The top three shareholder types of MaxCyte Inc are:
Cadian Capital Management LP
Mirabella Financial Services LLP
BlackRock Institutional Trust Company, N.A.
Cadian Capital Management LP
Mirabella Financial Services LLP
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of MaxCyte Inc (MXCT)?
As of 2025Q3, 287 institutions hold shares of MaxCyte Inc, with a combined market value of approximately 82.96M, accounting for 77.85% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 3.93%.
What is the biggest source of revenue for MaxCyte Inc?
In FY2025Q2, the Product sales business generated the highest revenue for MaxCyte Inc, amounting to 5.27M and accounting for 61.94% of total revenue.
